A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.

MLA

Büttner, Florian A., et al. “A Novel Molecular Signature Identifies Mixed Subtypes in Renal Cell Carcinoma with Poor Prognosis and Independent Response to Immunotherapy.” Genome Medicine, vol. 14, no. 1, Sept. 2022, p. 105. EBSCOhost, https://doi.org/10.1186/s13073-022-01105-y.

APA

Büttner, F. A., Winter, S., Stühler, V., Rausch, S., Hennenlotter, J., Füssel, S., Zastrow, S., Meinhardt, M., Toma, M., Jerónimo, C., Henrique, R., Miranda-Gonçalves, V., Kröger, N., Ribback, S., Hartmann, A., Agaimy, A., Stöhr, C., Polifka, I., Fend, F., … Schaeffeler, E. (2022). A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy. Genome Medicine, 14(1), 105. https://doi.org/10.1186/s13073-022-01105-y

Chicago

Büttner, Florian A, Stefan Winter, Viktoria Stühler, Steffen Rausch, Jörg Hennenlotter, Susanne Füssel, Stefan Zastrow, et al. 2022. “A Novel Molecular Signature Identifies Mixed Subtypes in Renal Cell Carcinoma with Poor Prognosis and Independent Response to Immunotherapy.” Genome Medicine 14 (1): 105. doi:10.1186/s13073-022-01105-y.